Medivir AB operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Medivir AB with three other
companies in this sector in Sweden:
Sprint Bioscience AB
sales of 23.97 million Swedish Kronor [US$2.62 million]
(48.00 million Swedish Kronor [US$5.25 million]
Bioinvent International AB
(45.01 million Swedish Kronor [US$4.92 million]
of which 100%
was Drug Development).
Medivir AB reported sales of SEK 36.64 million (US$4.01 million)
December of 2017.
decrease of 60.6%
versus 2016, when the company's sales were SEK 93.04 million.